Modulation of cell growth and PPARγ expression in human colorectal cancer cell lines by ciglitazone

Experimental and Toxicologic Pathology

Volumn 60, Issue 6, 2008, Pages 505-512

  Yaacob, Nik Soriani ^a   Darus, Halisa Mohd ^b   Norazmi, Mohd Nor ^b  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

Author keywords

Apoptosis; Ciglitazone; Colorectal cancer; Nuclear receptor; PPAR

Indexed keywords

CIGLITAZONE; CYTOKERATIN 18; LACTATE DEHYDROGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG INHIBITION; ENZYME RELEASE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIC AGENTS; L-LACTATE DEHYDROGENASE; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 49949095359     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.etp.2008.05.006     Document Type: Article

References (43)

1. Bantel H., Ruck P., Gregor M., and Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 80 (2001) 230-239
2. Brockman J.A., Gupta R.A., and DuBois R.N. Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells. Gastroenterology 115 (1998) 1049-1055
3. Caulin C., Salvesen G.S., and Oshima R.G. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138 (1997) 1379-1394
4. Chattopadhyay N., Singh D.P., Heese O., Godbole M.M., Sinohara T., Black P.M., et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARγ agonists as inducers of apoptosis. J Neurosci Res 61 (2000) 67-74
5. Chawla A., Schwarz E.J., Dimaculangan D.D., and Lazar M.A. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose predominant expression and induction early in adipocyte differentiation. Endocrinology 135 (1994) 798-800
6. DuBois R.N., Gupta R., Brockman J., Reddy B.S., Krakow S.L., and Lazar M.A. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 19 (1998) 49-53
7. Eibl G., Wente M.-N., Reber H.A., and Hines O.J. Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun 287 (2001) 522-529
8. Fajas L., Auboeuf D., Raspe E., Schoonjans K., Lefebvre A.-M., Saladin R., et al. The organization, promoter analysis and expression of the human PPARγ gene. J Biol Chem 272 (1997) 18779-18789
9. Fajas L., Fruchart J.C., and Auwerx J. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promotor. FEBS Lett 438 (1998) 55-60
10. Feilchenfeldt J., Brundler M.-A., Soravia C., Totsch M., and Meier C.A. Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARγ-coactivator 1 (PGC-1). Cancer Lett 203 (2004) 25-33
11. Feinstein D.L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gavrilyuk V., et al. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?. Biochem Pharmacol 70 (2005) 177-188
12. Fogh J., Wright W.C., and Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58 (1977) 209-214
13. Genini D., and Catapano C.V. Control of proxisome proliferator-activated receptor fate by the ubiquitin-proteasome system. J Recept Signal Transduct Res 26 (2006) 679-692
14. Greene M.E., Blumberg B., McBride O.W., Yi H.F., Kronquist K., Kwan K., et al. Isolation of the human peroxisome proliferator-activated receptor gamma cDNA: expression in hemaopoietic cells and chromosomal mapping. Gene Expression 4 (1995) 281-299
15. Hauser S., Adelmant G., Sarraf P., Wright H.M., Mueller E., and Spiegelman B.M. Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation. J Biol Chem 275 (2000) 18527-18533
16. Ikezoe T., Miller C.W., Kawano S., Heaney A., Williamson E.A., Hisatake J., et al. Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res 61 (2001) 5307-5310
17. Kato M., Kusumi T., Tsuchida S., Tanaka M., Sasaki M., and Kudo H. Induction of differentiation and peroxisome proliferator-activated receptor γ expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 130 (2004) 73-79
18. Koeffler H.P. Peroxisome proliferator-activated receptor γ and cancers. Clin Cancer Res 9 (2003) 1-9
19. Leers M.P.G., Kolgen W., Bjorklund V., Bergman T., Tribbick G., Persson B., et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187 (1999) 567-572
20. Lefebvre A.M., Chen I., Desremaux P., Najib J., Fruchart J.C., Geboes K., et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APC min/+ mice. Nat Med 4 (1998) 1053-1057
21. Melichar B., Konopleva M., Hu W., Karolina M., Andreef M., and Freedman R.S. Growth inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-diooxolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor γ expression. Gynecol Oncol 93 (2004) 149-154
22. Nakashiro K., Begum N.-M., Uchida D., Kawamata H., Shintani S., Sato M., et al. Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor γ. Oral Oncol 39 (2003) 855-861
23. Palakurthi S.S., Aktas H., Grubiddich L.M., Mortensen R.M., and Halperin J.A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61 (2001) 6213-6218
24. Perrey S., Ishibashi S., Yahagi N., Osuga J.-I., Tozawa R., Yagyu H., et al. Thiazolidedione- and tumor necrosis factor alpha-induced downregulation of peroxisome proliferator-activated receptor gamma mRNA in differentiated 3T3-L1 adipocytes. Metabolism 50 (2001) 36-40
25. Posch M.G., Zang C., Mueller W., Lass U., von Deimling A., and Elstner E. Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. Med Sci Monitor 10 (2004) BR250-BR254
26. Reichl F.-X., Walther U.I., Durner J., Kehe F., Hickel R., Kunzelmann K.-H., et al. Cytotoxicity of dental composite components and mercury compounds in lung cells. Dent Mater 17 (2001) 95-101
27. Rosen E.D., and Spiegelman B.M. PPARγ: a nuclear regulator of metabolism, differentiation and cell growth. J Biol Chem 276 (2001) 37731-37734
28. Rosenbaum S.E., and Greenberg A.S. The short- and long-term effects of tumor necrosis factor-α and BRL 49653 on peroxisome proliferator-activated receptor (PPAR) γ2 gene expression and other adipocyte genes. Mol Endocrinol 12 (1998) 1150-1160
29. Saez E., Tontonoz P., Nelson M.C., Alvarez J.G., Ming U.T., Baird S.M., et al. Activators of the nuclear receptor PPAR gamma enhanced colon polyp formation. Nat Med 4 (1998) 1058-1061
30. Sarraf P., Mueller E., Jones D., King F., DeAngelo D.J., Partridge J.B., et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 4 (1998) 1046-1052
31. Sarraf P., Mueller E., Smith W.M., Wright H.M., Kum J.B., Aaltonen L.A., et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell 3 (1999) 799-804
32. Semple T.U., Quinn L.A., Woods L., and Moore G.E. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res 38 (1978) 1345-1355
33. Shimada T., Kojima K., Yoshiura K., Hiraishi H., and Terano A. Characteristics of the peroxisome proliferator-activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut 50 (2002) 658-664
34. Sun Y., Tang X.M., Half E., Kuo M.T., and Sinicrope F.A. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells. Cancer Res 62 (2002) 6323-6328
35. Sundvold H., and Lien S. Identification of novel peroxisome proliferator-activated receptor (PPAR) gamma promoter in man and transactivation by the nuclear receptor RORalpha1. Biochem Biophys Res Commun 287 (2001) 383-390
36. Tang X., Sun Y.J., Half E., Kuo M.T., and Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 62 (2002) 4903-4908
37. Tipton D.A., Lyle B., Babich H., and Dabbous M.K. In vitro cytotoxic and anti-inflammatory effects of myrrh oil on human gingival fibroblasts and epithelial cells. Toxicol In Vitro 17 (2003) 1-10
38. Tontonoz H.P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
39. Toyoda M., Takagi H., Horiguchi N., Kakizaki S., Sato K., Takayama H., et al. A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 50 (2002) 563-567
40. Wang T., Xu J., Yu X., Yang R., and Han Z.C. Peroxisome proliferator-activated receptor g in malignant diseases. Crit Rev Oncol Hematol 58 (2006) 1-14
41. Yang W.L., and Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 22 (2001) 1379-1383
42. Yang F.G., Zhang Z.W., Xin D.Q., Shi C.J., Wu J.P., Guo Y.L., et al. Peroxiome proliferator-activated receptor gamma induces cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin 26 (2005) 753-761
43. Zhang X., and Young H.A. PPAR and immune system - what do we know?. Int Immunopharmacol 2 (2002) 1029-11044